FDA requires REMS plan for 25 drugs, biologics

Article

FDA issues a notice requiring the manufacturers of 25 high-risk drugs and biologics to submit a REMS plan.

In a notice published in the March 27

Related Videos
fake news misinformation | Image Credit: Bits and Splits - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.